NBTX

Investor Moves

Name	Value	Action	Change	Price	Last Price
Baillie GiffordInvestor $-14.3M ExitQ3 2024 $14M -- $39.80

News

seekingalpha.comNanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotechseekingalpha.comJun 12

globenewswire.comVoting Rights and Shares Capital of the Companyglobenewswire.comJun 5

globenewswire.comNanobiotix Provides First Quarter 2026 Operational and Financial Updateglobenewswire.comJun 2

globenewswire.comNanobiotix Joins the Euronext Tech Leaders Indexglobenewswire.comJun 2

globenewswire.comNANOBIOTIX Announces Closing of Global Offeringglobenewswire.comMay 26

Trade NBTX

About Nanobiotix S.A.

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

CEO: Laurent Levy
IPO Date: Dec 11, 2020

Market Data

Open: $36.22
High: $36.78
Low: $34.70
Volume: 49.5K
Avg Volume: 76.9K
52W High: $57.14
52W Low: $4.31

Valuation

Market Cap: $1.8B
Enterprise Value: $1.6B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$34M
Revenue: $29.6M
Net Income: -$24M
Cash: $52.8M
Debt: $95.3M

Events

EarningsSep 30

EPS est. -0.31556